Shuttle Pharmaceuticals (NASDAQ:SHPH) Rating Lowered to Strong Sell at Wall Street Zen

Shuttle Pharmaceuticals (NASDAQ:SHPH) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a report issued on Saturday.

Shuttle Pharmaceuticals Stock Performance

Shares of Shuttle Pharmaceuticals stock opened at $3.80 on Friday. The stock has a market cap of $1.67 million, a price-to-earnings ratio of -0.92 and a beta of -1.10. The stock has a 50 day moving average price of $5.46 and a 200-day moving average price of $12.47. Shuttle Pharmaceuticals has a one year low of $3.00 and a one year high of $107.40.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its earnings results on Thursday, May 8th. The company reported ($7.50) EPS for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .